TMO
January 31, 2024 - AI Summary
Undervalued by 2.3% based on the discounted cash flow analysis.
Market cap | $222.74 Billion |
---|---|
Enterprise Value | $249.58 Billion |
Dividend Yield | $1.4386 (0.25%) |
Earnings per Share | $15.45 |
Beta | 0.94 |
Outstanding Shares | 381,312,268 |
Avg 30 Day Volume | 1,364,770 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 37.15 |
---|---|
PEG | 1084.33 |
Price to Sales | 5.19 |
Price to Book Ratio | 4.76 |
Enterprise Value to Revenue | 5.82 |
Enterprise Value to EBIT | 34.38 |
Enterprise Value to Net Income | 41 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | 0.75 |
No data
No data
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are acceleratin...